



HAL
open science

Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients

Stéphane Jouneau, Chloé Rousseau, Mathieu Lederlin, Alain Lescoat, Mallorie Kerjouan, Pierre Chauvin, David Luque-Paz, Stéphanie Guillot, Emmanuel Oger, Laurent Vernhet, et al.

► To cite this version:

Stéphane Jouneau, Chloé Rousseau, Mathieu Lederlin, Alain Lescoat, Mallorie Kerjouan, et al.. Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. *Clinical Nutrition*, 2022, 41 (6), pp.1335-1342. 10.1016/j.clnu.2022.05.001 . hal-03689797

HAL Id: hal-03689797

<https://hal.science/hal-03689797>

Submitted on 30 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Malnutrition and decreased food intake at diagnosis are associated with hospitalization
and mortality of idiopathic pulmonary fibrosis patients**

Stéphane Jouneau,^{1,2} Chloé Rousseau,³ Mathieu Lederlin,^{4,5} Alain Lescoat,^{2,6} Mallorie
Kerjouan,¹ Pierre Chauvin,¹ David Luque-Paz,¹ Stéphanie Guillot,⁷ Emmanuel Oger,⁸ Laurent
Vernhet,^{2*} and Ronan Thibault.^{9*}

*Both authors contributed equally

¹Department of Respiratory Medicine, Competence Centre for Rare Pulmonary Diseases,
CHU Rennes, Rennes, France

²Univ Rennes, CHU Rennes, Inserm, EHESP, IRSET (Institut de recherche en santé,
environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

³Centre d'Investigation clinique, INSERM 1414, CHU Rennes, Univ Rennes, Rennes, France

⁴Department of Radiology, CHU Rennes, Univ Rennes, Rennes, France

⁵LTSI, INSERM U1099, Univ Rennes, Rennes, France

⁶Department of Internal Medicine & Clinical Immunology, CHU Rennes, Univ Rennes,
Rennes, France

⁷Department of Pulmonary function testing, CHU Rennes, Univ Rennes, Rennes, France

⁸Department of Pharmacology, CHU Rennes, Univ Rennes, Rennes, France

⁹INSERM, INRAE, Univ Rennes, Nutrition Metabolisms and Cancer, NuMeCan, Nutrition
unit, CHU Rennes, Rennes, France

Short title: Malnutrition and IPF outcomes

Correspondence:

1
2 Prof. Stéphane Jouneau
3

4 Service de pneumologie, Centre de Compétences pour les Maladies Rares Pulmonaires,
5
6 Hôpital Pontchaillou, UMR 1085, IRSET, Université de Rennes 1, 2 rue Henri Le Guilloux,
7
8
9 35033 Rennes Cedex 9, France
10

11 Stephane.jouneau@chu-rennes.fr
12
13
14
15

16
17 Prof. Ronan THIBAULT
18

19 Unité de Nutrition - Centre labellisé de Nutrition Parentérale à Domicile
20

21 CHU Rennes
22

23
24 2, rue Henri Le Guilloux
25

26 35000 Rennes
27

28
29 France
30

31 Tél. +33 2 99 28 96 46
32

33
34 Fax +33 2 99 28 24 34
35

36 E-mail ronan.thibault@chu-rennes.fr
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Highlights

1. The prevalence of malnutrition at idiopathic pulmonary fibrosis (IPF) is frequent (26%).
2. Malnutrition and decreased food intake at IPF diagnosis are associated with increased hospitalization and mortality but not acute exacerbation of IPF.
3. In multivariable analysis, baseline higher gender-age-physiology (GAP) scores, lower BMI, and decreased food intake (Self Evaluation of Food Intake (SEFI)[®] score) were independently associated with all-cause hospitalization and mortality rates during follow-up.

ABSTRACT

1
2 Introduction and aims: Malnutrition is frequent in patients with idiopathic pulmonary fibrosis
3 (IPF). We examined the relationship between malnutrition at diagnosis and all-cause
4 hospitalization, survival, and acute exacerbation in newly diagnosed IPF patients. Methods: In
5 this prospective cohort study, the nutritional status of 153 consecutive newly-diagnosed IPF
6 outpatients was evaluated by measuring body mass index (BMI), fat-free mass index (FFMI)
7 with bioelectrical impedance analysis, and food intake with the Self Evaluation of Food
8 Intake (SEFI)[®]. Diagnosis was taken as the baseline date and malnutrition was defined as an
9 FFMI below 17 (men) or 15 kg/m² (women). To determine the factors associated with all-
10 cause hospitalization and mortality, univariate Cox regression analyses were performed and
11 variables with P<0.2 were included in a stepwise multivariable analysis. Results: A quarter
12 (26%; 40/153) of the patients were suffering from malnutrition at baseline, which was more
13 frequent (62%) in patients whose BMI was <25 kg/m². Patients whose baseline FFMI was
14 low were more likely to be hospitalized (Hazard Ratio (HR)=1.98 [95% confidence interval,
15 1.15; 3.41], P=0.0139) and/or die (HR=1.79 [1.11; 2.89], P=0.0165), but their acute
16 exacerbation rate was similar to that of patients with normal FFMI. Decreased food intake
17 (SEFI[®]<7) at baseline was associated with all-cause hospitalization (P=0.003) and mortality
18 (P<0.0001) during follow-up. Baseline higher gender-age-physiology (GAP) scores (HR=1.24
19 [1.01;1.52], P=0.0434 ; HR=1.71 [1.37;2.14], P<0.0001, respectively), lower BMI (HR=0.89
20 [0.83;0.96], P=0.003 ; HR=0.89 [0.82; 0.96], P=0.003), and decreased food intake (SEFI[®]
21 score) (HR=0.81 [0.71;0.93], P=0.003 ; HR=0.72 [0.64;0.81], P<0.0001), but not FFMI, were
22 independently associated with all-cause hospitalization and mortality rates during follow-up.
23
24 Conclusions: Malnutrition and decreased food intake at IPF diagnosis are associated with all-
25 cause hospitalization and mortality. Future studies will determine whether dedicated
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 interventions to improve food intake and nutritional status could improve outcomes for IPF
2 patients.
3

4
5
6
7 **Keywords:** Appetite; weight; body composition; interstitial lung disease; nintedanib;
8
9 pirfenidone.
10

INTRODUCTION

1
2 Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease
3
4 with a poor prognosis (1). It is also the major cause of chronic idiopathic interstitial
5
6 pneumonia in adults (2). We previously used the fat-free mass index (FFMI), measured by
7
8 bioelectrical impedance analysis (BIA), to define malnutrition, as did for chronic obstructive
9
10 pulmonary disease (COPD) (3) to show that nearly one third of IPF patients are malnourished
11
12 (4). Malnutrition may have a negative impact on IPF prognosis. An initial study of 44 Asian
13
14 patients with IPF found that a low fat-free mass (FFM), assessed by BIA, was associated with
15
16 increased mortality (5). Although the BMI is a simple, widely used marker of nutritional
17
18 status, its value for predicting IPF outcome is still debated (5-10). It is not sensitive enough to
19
20 diagnose malnutrition: patients with a normal BMI (21-25 kg/m²) can have an increased fat
21
22 mass and a decreased FFM that it is not detected by BMI alone, leading to underestimated
23
24 malnutrition rates (4, 11). BIA, which measures body composition, including fat mass, muscle
25
26 mass and FFM, is a more accurate diagnostic tool and is recommended by the “The Global
27
28 Leadership Initiative on Malnutrition” (GLIM) as a phenotypic criterion of malnutrition
29
30 diagnosis (12).

31
32 The GLIM recommends assessing nutritional status by integrating five criteria defining
33
34 malnutrition: BMI, weight loss, loss of muscle mass (by BIA) or muscle function, plus
35
36 reduced food intake or an inflammatory disease such as IPF. The GLIM advocates using
37
38 semi-quantitative methods to assess food intake (12). We have found that a 10-point visual
39
40 analogue scale of food intake, the “Self-Evaluation of Food Intake” (SEFI®) is a simple tool
41
42 that correlates well with malnutrition for hospital in-patients and out-patients (13), and
43
44 primary care patients (14). The relationship between GLIM-evaluated malnutrition and the
45
46 clinical outcome of IPF has never been assessed. This prospective observational study was
47
48 done to determine whether malnutrition (defined by the etiologic factor “IPF, a chronic
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 disease”, and either one of two etiologic criteria: low FFMI or low BMI) and food intake, at
2 baseline, could predict the clinical outcome of IPF (hospitalization, death, acute exacerbation)
3
4 for a large population of Caucasian patients. We also assessed the evolution of their
5
6 nutritional status during follow-up.
7
8
9

10 11 **PATIENTS AND METHODS**

12 **Study design and patient recruitment**

13
14 This single-centre cohort study used prospective data. Data for all newly diagnosed IPF
15
16 patients referred to the Competence Centre for Rare Pulmonary Diseases (tertiary ILD
17
18 Centre), Department of Respiratory Medicine, Rennes University Hospital, Rennes, France by
19
20 general hospitals and private pulmonologists in Brittany between May 1, 2016 and December
21
22 31, 2019, were included.
23
24
25
26
27
28
29
30

31 **Study population**

32
33 Data for all the patients were collected when their IPF was diagnosed (baseline) and during
34
35 follow-up (1, 15). Unstable patients who had suffered a respiratory infection or exacerbation
36
37 in the eight weeks prior to diagnosis were excluded. This study was approved by the Rennes
38
39 CHU Ethics Committee (n°17.53).
40
41
42
43
44

45 **Clinical and biological assessment of nutritional status**

46
47 The nutritional status of all patients at diagnosis was assessed prospectively by a
48
49 pulmonologist (SJ) or a specialist outpatient clinic nurse by measuring weight, height, mid-
50
51 arm circumference (MAC) and triceps skinfold thickness (TSF). BMI was calculated as:
52
53 $\text{weight (kg) / height (m)}^2$. Malnutrition was defined as a BMI <21 kg/m², as recommended for
54
55 COPD patients (3, 16, 17). Mid-arm muscle circumference (MAMC) (cm) was calculated as:
56
57 $\text{MAC (cm) - }(\pi * \text{TSF (cm)})$. Food intake was systematically assessed with the Simple
58
59
60
61
62
63
64
65

1 Evaluation of Food Intake (SEFI)[®] ten-point analogue scale (French version) ([www.sefi-](http://www.sefi-nutrition.com)
2 [nutrition.com](http://www.sefi-nutrition.com)) (13). The result, between 0 and 10, is shown on the reverse side of the ruler. As
3
4 shown previously (13, 14), the SEFI[®] score below 7 indicates a reduced food intake. We
5
6 measured serum albumin (g/l), transthyretin (g/l), and C-reactive protein (CRP) (mg/l) as
7
8 markers of malnutrition and inflammation.
9
10

11 **Bioelectrical impedance analysis (BIA)**

12
13
14
15
16
17 Body composition was measured with a multifrequency bioimpedance generator/analyser
18
19 (Quadscan 4000, Bodystat Ltd, Isle of Man, UK)(4, 18) and the FFMI was calculated as: fat-
20
21 free mass (kg)/height (m)². Malnutrition was defined as an FFMI below the 25th percentile
22
23 (<17 kg/m² for men, <15 kg/m² for women) as recommended for COPD patients (3, 17) and
24
25 by international guidelines (12). The body fat mass index (BFMI) was calculated as: fat mass
26
27 (kg)/height (m)².
28
29
30
31
32
33

34 **Outcomes, respiratory and other data collection**

35
36 Outcomes, including all-cause hospitalization (date of the first unscheduled admission),
37
38 survival (death or transplantation), and acute exacerbation of IPF (AEIPF) were assessed on
39
40 December 31, 2019 to ensure a follow-up of at least 12 months for the most recently included
41
42 patient. Survival was defined as the time from initial diagnosis to death (19), with right-
43
44 censoring at the time of lung transplantation or at the end of the observation period for those
45
46 individuals who were alive and transplant-free.
47
48
49
50

51 We collected demographic (gender, age) and clinical data (disease duration, comorbidities,
52
53 current drug and/or tobacco use, any surgical lung biopsy), pulmonary function test (PFT) and
54
55 six-minute-walk test (6MWT) at baseline and during follow-up from the hospital medical
56
57 database. Dyspnoea was assessed using the New York Health Association (NYHA) scale.
58
59
60
61
62
63
64
65

1 PFT and 6MWT were performed according to international guidelines (20, 21). The gender,
2 age and physiology (GAP) scores and indices were calculated as proposed by Ley et al (22).
3
4
5

6 **Statistical analysis**

7
8
9 Descriptive statistics are given as means \pm standard deviations (SD) or medians and
10 interquartile ranges for continuous data and as the number of patients (percentages,
11 numerator/denominator counts) for categorical data. We analysed the FFM with χ^2 tests (or
12 Fisher's exact test) for categorical data, and Student's *t*-test (or Mann–Whitney–Wilcoxon
13 test) for continuous data. Mixed models were used to analyse the evolution of weight, BMI,
14 and FFMI for those patients with two or more evaluations.
15
16
17
18
19
20
21
22

23
24 Survival analyses included right censorship. Hazard ratios were calculated using a Cox model.
25
26 Univariate Cox regression analyses were performed and significant variables ($p < 0.2$) were
27 then included in a multivariate analysis, which was followed by backward stepwise
28 elimination. Univariate and multivariate analyses were performed for all-cause hospitalization
29 and survival. All statistics were calculated with SAS V9.4 software (SAS Institute Inc., Cary,
30 NC, USA), and two-tailed *P* values of <0.05 were considered statistically significant.
31
32
33
34
35
36
37
38
39
40

41 **RESULTS**

42 **Patient characteristics**

43
44 The clinical characteristics of the 153 patients with IPF (22% (34/153) women; 38% (58/153)
45 never-smokers) at diagnosis are shown in **Table 1**. The first 22 patients with BIA at baseline
46 had already been included in a cross-sectional study.(4) The overall mean age was 72.4 ± 8.1
47 years. The low FFMI of 26.1% (40/153) of the patients indicated that they were
48 malnourished. The mean FFMI of the women was 14.6 ± 2.2 kg/m² and that of the men was
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

19.2±2.2 kg/m². Those IPF patients with a low FFMI were older, more often female and never-smokers; they also had lower DLCO and higher GAP scores (**Table 1**).

The overall BMI at diagnosis was 26.8±4.0 kg/m² (**Table 2**) and patients with a low FFMI had a significantly lower BMI (22.7±2.7) than did those with a normal FFMI (28.3±3.4 kg/m², $P<0.0001$). All 7 patients whose BMI was <21 kg/m² had a low FFMI. More than two-thirds of patients with a low FFMI (28/40, 70.0%) had a normal BMI (≥ 21 and <25 kg/m²), and 5 (12.5%) were overweight (BMI ≥ 25 kg/m²). As previously shown, the mid-arm muscular circumference (MAMC) of patients with a low FFMI (26.3±2.5 cm) was smaller than that of patients with a normal FFMI (30.5±2.8 cm, $P<0.0001$). (4) The serum albumin, transthyretin and CRP concentrations of IPF patients with low and normal FFMI did not differ significantly.

Malnutrition at baseline and clinical outcomes

The mean follow-up time was 26 months (± 13), during which time 55 patients were hospitalized, 52 patients died and none was transplanted. Low-FFMI IPF patients were hospitalized earlier (survival probability without hospitalization: 23.8% [6.3; 47.6]) than were normal-FFMI patients (survival: 59.3% [45.4; 70.8]: HR=2.29 [1.33; 3.93], $P=0.0021$) (**Figure 1A**). The mortality rate of low-FFMI patients was higher (survival: 30.0% [7.4; 57.3]) than that of normal-FFMI patients (52.6% [36.4; 66.4], HR=1.83[1.04; 3.21]) (**Figure 1B**) but their AEIPF was not higher than that of normal-FFMI patients (**Figure 1C**). Outcomes are shown in **Table 3**.

The patients with a BMI of <21 kg/m² were more likely to die (survival: 38.1% [6.1; 71.6]) than were those whose BMI was ≥ 21 kg/m² (47.6% [33.0; 60.8], HR=2.96[1.06; 8.30]) (**Figure 2A**); they were also hospitalized earlier (survival: BMI <21 kg/m²: 25.0% [1.2; 64.6]; BMI >21 kg/m²: 50.5% [37.2; 62.3], HR=3.51[1.26; 9.81]) and more frequently exposed to

1 AEIPF (survival: BMI <21 kg/m²: 41.7% [1.1; 84.3]; BMI >21 kg/m²: 73.1% [59.8; 82.6],
2 HR=3.33[0.77; 14.32]). The mortality rates of patients with BMIs of <25 and ≥25 kg/m² were
3 similar (**Figure 2B**).
4

5 Patients whose food intake was decreased (SEFI®<7) were more likely to be hospitalized
6
7 (**Figure 3A**) and to die (**Figure 3B**) than were patients whose food intake was normal (SEFI®
8
9 ≥7).
10
11
12
13
14
15

16 **Evolution of nutritional status**

17 Mean body weight loss was 1.86 kg per year ($P<0.0001$). The decreases in FFMI (0.43
18
19 kg/m²/year, $P<0.0001$), and BFMI (0.23 kg/m²/year, $P=0.0017$) were also significant,
20
21 indicating that IPF patients lost both fat mass and FFM during the course of IPF. Antifibrotic
22
23 drugs had no impact on any of the nutritional parameters (data not shown).
24
25
26
27
28
29
30

31 **Factors associated with all-cause hospitalization**

32 Univariate analysis indicated that hospitalized patients had higher GAP scores and lower
33
34 FFMI, BMI, SEFI®, MAC, and BFMI values (**Table 4**); other variables were not significantly
35
36 different. Multivariate analyses revealed that the GAP score (HR=1.24; 95% CI 1.01; 1.52;
37
38 $P=0.0434$), BMI (HR=0.89; 95% CI 0.83; 0.96; $P=0.0033$), and food intake (SEFI®
39
40 HR=0.81; 95% CI 0.71; 0.93; $P=0.0027$) were independently associated with all-cause
41
42 hospitalization (**Table 4**).
43
44
45
46
47
48
49
50

51 **Death risk factors**

52 Univariate analysis (**Table 5**) indicated that patients who died had lower FFMI, BMI, FVC,
53
54 DLCO, SEFI®, MAMC, BFMI, serum albumin and transthyretin values, higher GAP scores,
55
56 cancer, and dyspnea, and were less frequently treated with antifibrotics. Multivariate analyses
57
58
59
60
61
62
63
64
65

1 found that the GAP score (HR=1.71; 95% CI 1.37; 2.14; $P<0.0001$), BMI (HR=0.89; 95% CI
2 0.82; 0.96; $P=0.0031$), and food intake (SEFI® HR=0.72; 95% CI 0.64; 0.81; $P<0.0001$) were
3
4 independently associated with death (**Table 5**).
5
6
7

8 9 **DISCUSSION**

10 This prospective study shows that the clinical outcomes for malnourished IPF patients (low
11 FFMI or BMI) and those whose food intake is decreased (SEFI® <7) at diagnosis are worse
12 than those for patients whose FFMI or food intake are normal, with higher mortality and
13 higher all-cause hospitalization rates but not higher acute IPF exacerbation rates. The mean
14 annual weight loss was almost 2 kg per year. The factors independently associated with
15 increased all-cause hospitalization and mortality were a high GAP score, low BMI, and low
16 SEFI® score, but not FFMI.
17
18
19
20
21
22
23
24
25
26
27

28 This study included the largest cohort ever evaluated for the impact of malnutrition at
29 diagnosis on the clinical outcomes of IPF patients.
30
31
32

33 All-cause hospitalization is a very important outcome for patients suffering from IPF; it
34 results in reduced patient survival and greater demand on healthcare resources, with
35 subsequent increased costs (23). In univariate analyses, but not multivariable analysis,
36 baseline low FFMI was found as a valuable predictor of all-cause hospitalization and
37 mortality during follow-up. Clearly, then, a systematic assessment of the nutritional status of
38 IPF patients at diagnosis and during follow-up, including data on weight, height, BMI, food
39 intake (SEFI®), and BIA is most important for detecting malnutrition and predicting clinical
40 outcome (19, 24). Although a BMI <21 kg/m² is used to define malnutrition in chronic
41 diseases, such as COPD (3, 16, 17), it is not sensitive enough to identify patients with a low
42 FFMI (7/40 (17%) in this study). BIA should therefore be part of the systematic nutritional
43 assessment of IPF patients. However, if BIA is not available, the nutritional assessment
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 should include the BMI, since our results indicate that almost two thirds of IPF patients with a
2 BMI $<25 \text{ kg/m}^2$ are malnourished and those whose BMI is $<21 \text{ kg/m}^2$ are much more likely to
3 die than patients with a BMI $\geq 21 \text{ kg/m}^2$. Malnourished IPF patients should be referred to
4 clinical nutritionists for a dedicated management.
5
6

7
8
9 The choice of the cutoff of $<25 \text{ kg/m}^2$ to define the BMI as associated with worse outcomes
10 was based on two reasons: i) our data distribution: indeed only seven patients had a BMI <21
11 kg/m^2 , and no patient with BMI $<21 \text{ kg/m}^2$ had a normal FFMI (Table 2); ii) our recent
12 publication (8) reporting that IPF patients with a baseline BMI $<25 \text{ kg/m}^2$ or annualized
13 weight loss of >0 - $<5\%$ or $\geq 5\%$ may experience worse outcomes over 1 year *versus* those with
14 a baseline BMI $\geq 25 \text{ kg/m}^2$ or no weight loss.
15
16
17
18
19
20
21
22
23

24 We find that decreased food intake is associated with a poor prognosis for IPF patients. A low
25 food intake is now considered by the GLIM as an etiologic criterion of malnutrition diagnosis
26 (12). The SEFI® is a simple, easy tool for assessing food intake (13) and malnutrition (14) in
27 outpatients, inpatients, and in general/private practice (13, 14). Low food intake and increased
28 short-term mortality have also been shown to be associated in a large cohort of hospitalized
29 patients (25). Decreased food intake can be a marker of disease severity (25) and malnutrition
30 (13, 14). IPF is a chronic inflammatory disease and sufferers are at risk of malnutrition due to
31 the progressive depletion of muscle protein stores, leading to decreased fat-free mass reserves,
32 and anorexia/reduced food intake.
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Several studies have examined the relationship between malnutrition and mortality for
47 Caucasian and Asian IPF patients (6, 9, 26). Nutritional status was assessed by measuring
48 BMI or weight loss but the BMI provided contradictory results. Nakatsuka et al. found that a
49 $>5\%$ weight loss was associated with poor survival and that a weight loss $>6.1\%$ was an
50 independent predictor of mortality (26). We have also shown that the FVCs of IPF patients
51 whose weight loss is $>5\%$ in the placebo group of INPULSIS trials declined faster than those
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 of patients whose weight loss was $\leq 5\%$ (7). But we found no association between weight loss
2 and mortality (7). In the present study, the survival curves (Kaplan-Meier) of IPF patients
3 who lost $>2\text{kg}$ and those who lost no weight or $< 2\text{ kg}$ were not statistically different (data not
4 shown). These differences may be due to a lack of statistical power in our present data. To our
5 knowledge, only one study on 44 Asian IPF patients has investigated the association between
6 FFMI and mortality (5). The authors reported that patients with below-median FFMI values
7 ($<16.6\text{ kg/m}^2$) survived less well than patients whose FFMI was above the median, but they
8 did not use the validated cut-offs proposed by the GLIM (12). Our study of a large cohort of
9 Caucasian patients clearly indicates the link between malnutrition at diagnosis and mortality
10 in IPF patients.
11

12 The pathophysiological mechanisms underlying the relationship between IPF and
13 malnutrition are not well understood. Malnutrition and loss of muscle mass could be due to
14 the pulmonary disease itself, as the progression of IPF and dyspnoea reduces exercise
15 capacity, muscle strength and overall physical activity (27, 28). These changes could
16 exacerbate dyspnea, resulting in a vicious circle and greater malnutrition. Further research is
17 needed to identify the molecular mechanisms mediating malnutrition in IPF patients.
18

19 Fewer of our low-FFMI patients were treated with antifibrotics than were those with a normal
20 FFMI. Perhaps pulmonologists should consider these patients as having an unfavourable
21 risk/benefit balance against therapy. Nintedanib and pirfenidone can have potent side effects,
22 including anorexia, body weight loss, fatigue, diarrhoea or abdominal pain, and these adverse
23 effects can influence a patient's nutritional status, increasing the severity of malnutrition (2,
24 10, 29-33). In contrast, recent findings indicate that nintedanib protects the lung function of
25 malnourished IPF patients. Post-hoc analyses of INPULSIS trial data revealed that the FVC of
26 placebo group patients who lost $>5\%$ body weight declined more than that of patients who
27 lost $\leq 5\%$ body weight but that this decrease in lung function did not occur in the nintedanib-

1 treated patients (7). Similarly, the FVC of placebo group patients with a baseline BMI of <25
2 kg/m² decreased faster than that of patients with a baseline BMI of ≥25 kg/m² (7).
3

4 The strength of this study is that we used a global assessment of nutritional status as
5 recommended by the GLIM (12). Our database was built prospectively with very few missing
6 data. The pulmonologists, nutritionists, radiologists, scientists, PFT specialists, and nurses in
7 our IPF tertiary care centre facilitated all stages of the study, from design to analysis.
8
9 Nevertheless, this study has limitations. All the patients were from a single area, so the results
10 need to be confirmed for other IPF populations. Second, we collected no molecular biology
11 data (cytokines/chemokines) and so can only speculate about the pathophysiological
12 mechanisms driving malnutrition in IPF patients. To study the FFMI, we used the cut-off
13 points recommended by the GLIM consensus (12) rather than the ones used in COPD patients
14 to predict mortality (16/15 (3) or 17.0/14.62 kg/m² (17) for males/females, respectively). This
15 could have possibly slightly influenced our results. Finally, we did not record the causes of
16 death.
17
18

19 To conclude, malnutrition and decreased food intake at diagnosis are associated with all-cause
20 hospitalization and mortality in IPF patients. Further studies will determine whether dedicated
21 intervention to improve food intake and nutritional status could improve outcomes for IPF
22 patients.
23
24
25
26
27
28
29
30
31
32
33

34 **Statement of authorship**

35 All the authors made substantial contributions: SJ and RT conceived and designed the study.
36
37 SJ collected the data; SJ, CR, DLP, ML, EO, LV and RT analysed the data. SJ, LV and RT
38 wrote the manuscript to which the other authors added substantial modifications. All the
39 authors approved the final submitted version.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Conflict of interest statement

1
2 Stéphane Jouneau has received fees, funding or reimbursement for national and international
3
4 conferences, boards, expert or opinion groups, and research projects over the past 5 years
5
6 from Actelion, AIRB, Astra Zeneca, Bellorophon Therapeutics, Biogen, BMS, Boehringer,
7
8 Chiesi, Fibrogen, Gilead, GSK, LVL, Mundipharma, Novartis, Olam Pharm, Pfizer, Pliant
9
10 Therapeutics, Roche, Savara-Serendex.
11

12
13
14 Mathieu Lederlin has received fees, funding or reimbursement for national and international
15
16 conferences, boards, expert or opinion groups and research projects over the past 5 years from
17
18 Astra Zeneca, Boehringer, Fresenius-Kabi, Roche, and Siemens Healthcare
19

20
21
22 Laurent Vernhet has received funding from Boehringer-Ingelheim for research projects.
23

24
25 Ronan Thibault has received royalties for designing the Simple Evaluation of Food Intake®
26
27 (SEFI®) (Knoë, le Kremlin Bicêtre, France) tool, and consulting fees from Roche.
28

29
30 The other authors disclose no conflict of interest.
31

Funding

32
33
34
35
36 The ‘Association pour l’aide aux insuffisants respiratoires de Bretagne (AIRB)’ and Roche
37
38 Pharma provided the bioelectrical impedance analysers. This study had no other funding.
39
40

Acknowledgements

41
42
43
44
45
46 The authors thank also Cécile Daoudal, our outpatient clinic nurse, for her invaluable
47
48 contribution, and Dr Owen Parkes for editing the English text.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med*. 2011;183(6):788-824.
2. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. *Eur Respir J*. 2015;46(4):1113-30.
3. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. *Am Rev Respir Dis*. 1993;147(5):1151-6.
4. Jouneau S, Kerjouan M, Rousseau C, Lederlin M, Llamas-Gutierrez F, De Latour B, et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center. *Nutrition*. 2019;62:115-21.
5. Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H, et al. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. *Respirology*. 2017;22(3):480-5.
6. Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. *Chest*. 2007;131(5):1448-53.
7. Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. *Respir Res*. 2020;21(1):312.
8. Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Yang M, et al. Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-Treated Patients with IPF Stratified by BMI and Weight Loss. *Respiration*. 2022;101(2):142-54.
9. Kishaba T, Nagano H, Nei Y, Yamashiro S. Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. *J Thorac Dis*. 2016;8(12):3596-604.
10. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;370(22):2071-82.
11. Schols AM, Broekhuizen R, Welting-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. *Am J Clin Nutr*. 2005;82(1):53-9.
12. Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. *Clin Nutr*. 2019;38(1):1-9.
13. Thibault R, Goujon N, Le Gallic E, Clairand R, Sebille V, Vibert J, et al. Use of 10-point analogue scales to estimate dietary intake: a prospective study in patients nutritionally at-risk. *Clin Nutr*. 2009;28(2):134-40.
14. Bouette G, Esvan M, Apel K, Thibault R. A visual analogue scale for food intake as a screening test for malnutrition in the primary care setting: Prospective non-interventional study. *Clin Nutr*. 2021;40:174-80.
15. Cottin V, Crestani B, Valeyre D, Wallaert B, Cadranel J, Dalphin JC, et al. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. *Eur Respir Rev*. 2014;23(132):193-214.
16. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease. 2017. <http://www.goldcopd.com>.
17. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. *Am J Respir Crit Care Med*. 2006;173(1):79-83.
18. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, et al. Bioelectrical impedance analysis--part I: review of principles and methods. *Clin Nutr*. 2004;23(5):1226-43.
19. Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, et al. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. *Eur Respir J*. 2019;53(3).

20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26(2):319-38.
21. A. T. S. Committee. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166(1):111-7.
22. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med*. 2012;156(10):684-91.
23. Nathan SD, Meyer KC. IPF clinical trial design and endpoints. *Curr Opin Pulm Med*. 2014;20(5):463-71.
24. Jouneau S, Lederlin M, Vernhet L, Thibault R. Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity! *Eur Respir J*. 2019;53(5).
25. Hiesmayr M, Schindler K, Pernicka E, Schuh C, Schoeniger-Hekele A, Bauer P, et al. Decreased food intake is a risk factor for mortality in hospitalised patients: the NutritionDay survey 2006. *Clin Nutr*. 2009;28(5):484-91.
26. Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, et al. The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients. *Respiration*. 2018;96(4):338-47.
27. Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H, et al. Physical activity in daily life in patients with idiopathic pulmonary fibrosis. *Respir Investig*. 2018;56(1):57-63.
28. Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, et al. Clinical Correlates of Reduced Physical Activity in Idiopathic Pulmonary Fibrosis. *Respiration*. 2016;91(6):497-502.
29. Cottin V, Crestani B, Cadranet J, Cordier JF, Marchand-Adam S, Prevot G, et al. [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. 2017 update. Full-length update]. *Rev Mal Respir*. 2017.
30. Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, et al. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. *ERJ Open Res*. 2018;4(4).
31. Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. *Lancet Respir Med*. 2018.
32. King TE, Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;370(22):2083-92.
33. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet*. 2011;377(9779):1760-9.

Table 1- Clinical and demographic characteristics of idiopathic pulmonary fibrosis (IPF) patients at diagnosis. Malnutrition is defined as a low FFMI: <17 kg/m² (men) and <15 kg/m² (women).

Variables	All patients (n=153)	Low FFMI (n=40)	Normal FFMI (n=113)	Odds ratio [95% confidence interval]	P value
Age (years)	72.4 ± 8.1 (50.3; 66.9; 73.6; 78.3; 88.8)	75.5 ± 6.4 (60.4; 70.5; 75.0; 80.5; 88.8)	71.3 ± 8.4 (50.3; 65.3; 72.5; 77.5; 85.9)	1.07 [1.02 – 1.13]	0.0059
Male	119 (77.8%)	22 (55.0%)	97 (85.8%)	0.20 [0.09 – 0.46]	0.0001
Smoker	95 (62.1%)	13 (32.5%)	82 (72.6%)	0.18 [0.08 – 0.40]	< 0.0001
Cough	93 (60.8%)	28 (70.0%)	65 (57.5%)	1.72 [0.80 – 3.73]	0.1675
Dyspnea (NYHA stages)					
I	25 (16.3%)	4 (10.0%)	21 (18.6%)	Reference	0.2644
II	53 (34.6%)	14 (35.0%)	39 (34.5%)	1.88 [0.55 – 6.46]	
III	65 (42.5%)	17 (42.5%)	48 (42.5%)	1.86 [0.56 – 6.20]	
IV	10 (6.5%)	5 (12.5%)	5 (4.4%)	5.25 [1.02 – 26.98]	
Digital clubbing	42 (27.5%)	12 (30.0%)	30 (26.5%)	1.19 [0.54 – 2.63]	0.6744
FVC (% pred)	81.7 ± 17.5 (42.0; 69.0; 82.0; 93.0; 132.0)	77.7 ± 20.1 (47.0; 64.5; 76.0; 87.0; 132.0)	83.1 ± 16.3 (42.0; 71.0; 85.0; 96.0; 122.0)	0.98 [0.96 – 1.00]	0.0941

Variables	All patients (n=153)	Low FFMI (n=40)	Normal FFMI (n=113)	Odds ratio [95% confidence interval]	P value
DLCO (% pred)	45.4 ± 16.8 (8.0; 36.0; 46.0; 57.0; 108.0)	37.3 ± 18.2 (8.0; 25.5; 38.0; 51.0; 73.0)	48.3 ± 15.3 (8.0; 40.0; 47.0; 57.0; 108.0)	0.96 [0.93 – 0.98]	0.0006
GAP index	3.9 ± 1.4 (0.0; 3.0; 4.0; 5.0; 8.0)	4.4 ± 1.4 (2.0; 3.0; 4.0; 5.5; 8.0)	3.7 ± 1.3 (0.0; 3.0; 4.0; 4.5; 8.0)	1.45 [1.09 – 1.92]	0.0100
GAP class					
1	59 (38.8%)	13 (32.5%)	46 (41.1%)	Reference	0.0292
2	74 (48.7%)	17 (42.5%)	57 (50.9%)	1.06 [0.46 – 2.40]	
3	19 (12.5%)	10 (25.0%)	9 (8.0%)	3.93 [1.32 – 11.70]	
Surgical lung biopsy	37 (24.2%)	6 (15.0%)	31 (27.4%)	0.47 [0.18 – 1.22]	0.1203
Cancer	10 (6.6%)	2 (5.1%)	8 (7.1%)	0.70 [0.14 – 3.46]	0.6646
Cardiovascular comorbidities*	106 (69.3%)	26 (65.0%)	80 (70.8%)	0.77 [0.36 – 1.65]	0.4953
Charlson comorbidity index	1.4 ± 1.4 (0.0; 0.0; 1.0; 2.0; 9.0)	1.3 ± 1.3 (0.0; 0.0; 1.0; 2.0; 4.0)	1.4 ± 1.4 (0.0; 0.0; 1.0; 2.0; 9.0)	0.97 [0.75 – 1.27]	0.8466
Corticosteroid use	8 (5.3%)	5 (12.5%)	3 (2.7%)	5.19 [1.18 ; 22.83]	0.0293
Antifibrotics during follow-up					
Yes	96 (62.7%)	20 (50.0%)	76 (67.3%)	0.49 [0.23 – 1.01]	0.0545

Variables	All patients (n=153)	Low FFMI (n=40)	Normal FFMI (n=113)	Odds ratio [95% confidence interval]	<i>P</i> value
No	57 (37.3%)	20 (50.0%)	37 (32.7%)	Reference	
Nintedanib	58 (37.9%)	13 (32.5%)	45 (39.8%)	0.53 [0.23 – 1.22]	0.1444
Pirfenidone	38 (24.8%)	7 (17.5%)	31 (27.4%)	0.42 [0.16 – 1.12]	
None	57 (37.3%)	20 (50.0%)	37 (32.7%)	Reference	

Qualitative variable: number (%). Quantitative variable: mean \pm standard deviation (min; Q1; median; Q3; max). FFMI, fat-free mass index; FVC, forced vital capacity; GAP index, the gender, age and physiology index; DLCO, diffusing lung capacity for carbon monoxide; % pred; percentage of predicted values. Missing data: FVC, n=2; DLCO, n=2; GAP index and class, n=1; Cancer, n=2.

*Cardiovascular comorbidities included especially high blood pressure, history of stroke, myocardial infarction, atrial fibrillation.

Table 2- Nutritional status of idiopathic pulmonary fibrosis (IPF) patients at diagnosis. Malnutrition is defined as a low FFMI: <17 kg/m² (men) and <15 kg/m² (women).

Variables	All patients (n=153)	Low FFMI (n=40)	Normal FFMI (n=113)	Odds ratio [95% confidence interval]	<i>P</i> value
Clinical parameters					
Weight (kg)	75.5 ± 14.4 (41.4; 65.0; 75.0; 84.0; 115.0)	59.1 ± 7.4 (41.4; 54.5; 60.0 ; 64.0 ; 75.0)	81.3 ± 11.6 (55.0; 73.0; 81.5; 87.0; 115.0)	0.72 [0.63 – 0.81]	<0.0001
Body mass index (kg/m ²)	26.8 ± 4.0 (16.4;24.0; 27.1; 29.4; 38.3)	22.7 ± 2.7 (16.4; 21.1; 22.6 ; 24.2; 28.9)	28.3 ± 3.4 (22.2; 25.7; 28.4; 30.1; 38.3)	0.50 [0.39 – 0.64]	<0.0001
Body mass index < 21 kg/m ²					
No	146 (95.4%)	33 (82.5%)	113 (100.0%)	Reference	
Yes	7 (4.6%)	7 (17.5%)	0 (0.0%)	50.77 [2.33 – 1108.46]	0.0125
SEFI® score	9.0 ± 1.9 (0.0 8.0; 10.0; 10.0; 10.0)	8.9 ± 2.1 (0.0; 8.0; 10.0; 10.0; 10.0)	9.0 ± 1.8 (3.0; 8.0; 10.0; 10.0; 10.0)	0.95 [0.79 – 1.15]	0.6116
SEFI® score < 7					
No	131 (86.2%)	34 (85.0%)	97 (86.6%)	Reference	
Yes	21 (13.8%)	6 (15.0%)	15 (13.4%)	1.14 [0.41 – 3.18]	0.8005
Mid-arm circumference (cm)	31.0 ± 3.3 (23.0 ; 28.5 ; 31.0 ; 33.0; ; 40.0)	27.7 ± 2.3 (23.0; 26.0 ; 28.0 ; 29.0 ; 34.0)	32.2 ± 2.8 (27.0 ; 30.0 ; 32.0 ; 34.0 ; 40.0)	0.44 [0.33 – 0.59]	<0.0001

Variables	All patients (n=153)	Low FFMI (n=40)	Normal FFMI (n=113)	Odds ratio [95% confidence interval]	<i>P</i> value
TSF (mm)	5.0 ± 3.0 (1.0 ; 3.0 ; 4.0 ; 6.0 ; 19.0)	4.5 ± 2.7 (2.0 ; 3.0 ; 4.0 ; 5.0 ; 14.0)	5.2 ± 3.0 (1.0 ; 3.0 ; 4.0 ; 6.0 ; 19.0)	0.91 [0.79 – 1.05]	0.1943
MAMC (mm)	294.1 ± 33.4 (211.2 ; 270.6 ; 294.0 ; 315.3 ; 396.9)	262.8 ± 24.9 (211.2 ; 244.0 ; 265.2 ; 279.9 ; 330.6)	305.5 ± 28.4 (248.6 ; 284.9 ; 302.7 ; 323.7 ; 396.9)	0.93 [0.91 – 0.96]	<0.0001
Bioimpedance analysis					
50 kHz phase angle (degree)	5.5 ± 1.4 (3.3 ; 4.8 ; 5.4 ; 5.9 ; 17.1)	4.9 ± 0.8 (3.3 ; 4.3 ; 5.0 ; 5.5 ; 6.4)	5.7 ± 1.5 (3.7 ; 5.0 ; 5.5 ; 6.0 ; 17.1)	0.39 [0.24 – 0.65]	0.0003
BFMI (kg/m ²)	8.6 ± 2.6 (4.0 ; 6.9 ; 8.2 ; 10.1 ; 18.9)	8.0 ± 2.7 (4.0 ; 5.8 ; 7.4 ; 9.9 ; 14.7)	8.8 ± 2.6 (4.3 ; 7.1 ; 8.4 ; 10.3 ; 18.9)	0.88 [0.75 – 1.02]	0.0950
FFMI (kg/m ²)					
Women	14.6 ± 2.2 (10.4 ; 13.2 ; 14.7 ; 16.1 ; 19.5)	13.0 ± 1.4 (10.4 ; 11.9 ; 13.3 ; 14.3 ; 14.8)	16.4 ± 1.2 (15.1 ; 15.6 ; 16.1 ; 17.0 ; 19.5)	0.01 [0.00 ; 0.75]	0.0378
Men	19.2 ± 2.2 (14.2 ; 17.8 ; 19.5 ; 20.9 ; 25.1)	16.1 ± 0.7 (14.2 ; 16.0 ; 16.3 ; 16.6 ; 16.9)	19.9 ± 1.7 (17.0 ; 18.5 ; 20.0 ; 21.0 ; 25.1)	0.00 [0.00 ; 1.87]	0.0623

Variables	All patients (n=153)	Low FFMI (n=40)	Normal FFMI (n=113)	Odds ratio [95% confidence interval]	P value
Biological parameters					
Serum albumin (g/L)	43.2 ± 2.9 (34.3 ; 41.8 ; 43.5 ; 45.4 ; 49.8)	43.3 ± 2.5 (35.8 ; 42.4 ; 43.6 ; 45.3 ; 47.5)	43.2 ± 3.0 (34.3 ; 41.7 ; 43.4 ; 45.5 ; 49.8)	1.02 [0.90 – 1.16]	0.7534
Serum transthyretin (g/L)	0.2 ± 0.1 (0.1 ; 0.2 ; 0.3 ; 0.3 ; 0.4)	0.2 ± 0.1 (0.2 ; 0.2 ; 0.3 ; 0.3 ; 0.4)	0.3 ± 0.1 (0.1 ; 0.2 ; 0.3 ; 0.3 ; 0.4)	0.92 [0.46 – 1.84]	0.8054
C reactive protein (mg/L)	6.3 ± 13.0 (1.0 ; 1.5 ; 2.7 ; 6.2 ; 107.0)	3.4 ± 4.5 (1.0 ; 1.0 ; 2.0 ; 3.3 ; 25.9)	7.3 ± 14.7 (1.0 ; 1.9 ; 3.3 ; 7.1 ; 107.0)	0.92 [0.83 – 1.02]	0.0990

Qualitative variable: number (%). Quantitative variable: mean ± standard deviation (min; Q1; median; Q3; max). BFMI, body fat mass index ; FFMI, fat-free mass index; MAMC, mid-arm muscular circumference; SEFI®, Simple Evaluation of Food Intake®; TSF, triceps skinfold thickness. Missing data: SEFI®, n=1; TSF, n=3; MAMC, n=3; serum albumin, n=3; serum transthyretin, n=4; C reactive protein, n=4.

Table 3: Outcomes of patients with idiopathic pulmonary fibrosis (IPF) according to their fat-free mass index (FFMI). Malnutrition is defined as a low FFMI: <17 kg/m² (men and <15 kg/m² (women). No missing data.

Variables	All patients (n=153)	Low FFMI (n=40)	Normal FFMI (n=113)	<i>P</i> value
All cause-hospitalization	55 (35.9%)	22 (55.0%)	33 (29.2%)	0.0035
Death	52 (34.0%)	19 (47.5%)	33 (29.2%)	0.0358
Acute exacerbation of IPF	26 (17.0%)	8 (20.0%)	18 (15.9%)	0.5558

Table 4: Univariate and multivariate analyses of baseline factors associated with all-cause hospitalization. Logistic regression multivariate analysis followed by backward stepwise selection. Multivariate analysis identified two significant variables associated with all-cause hospitalization: FFMI and ICW (continuous variables).

Variables	N total	All-cause hospitalization	HR [CI95%]	Univariate P-value	Multivariate P-value
Age	153	55	1.00 [0.97 ; 1.04]	0.8398	
Male	119	44	1.22 [0.63 ; 2.37]	0.5527	
FVC (% predicted)	151	54	0.98 [0.96 ; 0.99]	0.0099	
DLCO (% predicted)	151	54	0.97 [0.95 ; 0.99]	0.0006	
GAP score	152	54	1.34 [1.09 ; 1.65]	0.0052	0.0434
Cancer	10	5	2.11 [0.83 ; 5.33]	0.1150	
Smoker	95	33	0.87 [0.50 ; 1.48]	0.5988	
Dyspnea (NYHA stage)	153	55		0.1397	
4	10	5	1		
1	25	10	0.47 [0.17 ; 1.36]		
2	53	17	0.35 [0.13 ; 0.93]		
3	65	23	0.35 [0.13 ; 0.90]		
Charlson comorbidity index	152	55	1.09 [0.92 ; 1.29]	0.3318	
Antifibrotic drug during follow-up	96	32	0.72 [0.42 ; 1.22]	0.2217	
Body mass index (kg/m ²)	153	55	0.90 [0.84 ; 0.97]	0.0055	0.0033
SEFI®	152	54	0.82 [0.72 ; 0.93]	0.0030	0.0027
MAC (cm)	153	55	0.92 [0.84 ; 1.00]	0.0410	
MAMC (mm)	150	55	0.99 [0.99 ; 1.00]	0.1469	
Phase angle (degree)	153	55	0.85 [0.65 ; 1.12]	0.2390	
Normal FFMI	113	33	0.44 [0.25 ; 0.75]	0.0027	
BFMI (kg/m ²)	153	55	0.87 [0.78 ; 0.98]	0.0261	
Serum albumin (g/L)	150	54	0.93 [0.84 ; 1.03]	0.1905	
Serum transthyretin (g/L)	149	53	0.66 [0.39 ; 1.13]	0.1330	
CRP (mg/L)	149	53	1.00 [0.98 ; 1.02]	0.9739	

BFMI, body fat mass index; DLCO, diffusing lung capacity for carbon monoxide; % pred, percentage of predicted values. FFMI, fat-free mass index; FVC, forced vital capacity; GAP score, gender, age and physiology score; MAMC, mid-arm muscular circumference; SEFI®, Simple Evaluation of Food Intake®; TSF, triceps

skinfold thickness.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 5: Univariate and multivariate analyses of baseline factors associated with death.

Logistic regression multivariate analysis followed by backward stepwise selection.

Multivariate analysis identified three variables significantly associated with poorer survival:

high GAP score, low body mass index (BMI) and low score of the Simple Evaluation of Food Intake (SEFI)®.

Variables	N total	Death	HR [CI95%]	Univariate P-value	Multivariate P-value
Age	153	52	1.03 [0.99; 1.07]	0.1070	
Male	119	45	1.95 [0.88; 4.33]	0.1002	
FVC	151	50	0.96 [0.94; 0.98]	<0.0001	
DLCO	151	51	0.95 [0.94; 0.97]	<0.0001	
GAP score	152	51	1.91 [1.55; 2.35]	<0.0001	<0.0001
Cancer	10	6	3.46 [1.46; 8.24]	0.0049	
Smoker	95	29	0.72 [0.42; 1.25]	0.2498	
Dyspnea (NYHA stage)	153	52		0.0117	
4	10	7	1		
1	25	5	0.09 [0.06; 0.60]		
2	53	16	0.26 [0.11; 0.64]		
3	65	24	0.31 [0.13; 0.72]		
Digital clubbing	42	18	1.88 [1.06; 3.35]	0.0320	
Charlson comorbidity index	152	52	1.08 [0.90 ; 1.28]	0.4107	
Antifibrotic drug during follow-up	96	26	0.52 [0.30; 0.90]	0.0200	
BMI (kg/m ²)	153	52	0.88 [0.82; 0.95]	0.0010	0.0031
SEFI®	152	52	0.72 [0.64; 0.80]	<0.0001	<0.0001
MAMC (mm)	150	52	0.99 [0.98; 1.00]	0.0297	
Phase angle (degree)	153	52	0.80 [0.59; 1.08]	0.1481	
Normal FFMI	113	33	0.55 [0.31; 0.96]	0.0368	
BFMI (kg/m ²)	153	52	0.80 [0.70; 0.91]	0.0011	
Serum albumin (g/L)	150	51	0.87 [0.80; 0.96]	0.0048	
Serum transthyretin (g/L)	149	50	0.43 [0.25; 0.75]	0.0031	
CRP (mg/L)	149	51	1.01 [0.99; 1.03]	0.4982	

1 Qualitative variable: number (%). Quantitative variable: mean \pm standard deviation (min; Q1;
2 median; Q3; max). BFMI, body fat mass index; BMI, body-mass index; CRP, C-reactive
3 protein; DLCO: diffusing lung capacity for carbon monoxide; ECW, extracellular water;
4 FVC, forced vital capacity; F, female; FFMI, fat-free mass index; GAP, gender – age –
5 physiology; ICW, intracellular water; M, male; MAC, mid-arm circumference; MAMC, mid-
6 arm muscular circumference; SEFI®, Simple Evaluation of Food Intake®; TBW, total body
7 water; TSF, triceps skinfold thickness.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure legends

1
2
3
4
5 **Figure 1- Kaplan-Meier curves of main clinical outcomes for patients with a low or**
6 **normal FFMI. A. All-cause hospitalization. B. Survival (mortality). C. Acute**
7 **exacerbation of IPF.** Low-FFMI IPF patients (dotted line) were more frequently hospitalized
8 and more likely to die – but did not have more acute exacerbation of IPF – than for normal
9 FFMI patients (full line).
10
11
12
13
14
15
16
17
18

19 **Figure 2- Kaplan-Meier curves of Survival (mortality) of IPF patients compared with**
20 **BMI cut-offs.** The survival rate of patients with a BMI<21 was lower (38.1% [6.1; 71.6])
21 than that of patients with a BMI \geq 21 (47.6% [33.0; 60.8]) (Figure 2A). Patients with BMIs of
22 < and \geq 25 had similar mortality rates (54.6% [37.6%;68.7%] versus 33.7% [12.2%;56.9%]
23 respectively, Figure 2B).
24
25
26
27
28
29
30
31
32
33

34 **Figure 3- Kaplan-Meier curves of all-cause hospitalization (3A) and mortality (3B) of**
35 **IPF patients whose food intake was low (SEFI® < 7) and normal (SEFI® \geq 7).** More
36 patients with a SEFI® < 7 (dotted line) were hospitalized and died than were patients with
37 SEFI® \geq 7 (full line).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1




Figure 2







Figure 3





Click here to access/download
ICMJE Conflict of Interest
Jouneau_coi_disclosure.pdf





Click here to access/download
ICMJE Conflict of Interest
Rousseau_coi_disclosure.pdf






Click here to access/download
ICMJE Conflict of Interest
Lederlin_coi_disclosure.pdf








Click here to access/download
ICMJE Conflict of Interest
Lescoat_coi_disclosure.pdf





Click here to access/download
ICMJE Conflict of Interest
Kerjouan_coi_disclosure.pdf






Click here to access/download
ICMJE Conflict of Interest
Chauvin_coi_disclosure.pdf





Click here to access/download
ICMJE Conflict of Interest
Luque-Paz_coi_disclosure.pdf





Click here to access/download
ICMJE Conflict of Interest
Guillot_coi_disclosure.pdf





Click here to access/download
ICMJE Conflict of Interest
Oger_coi_disclosure.pdf





Click here to access/download
ICMJE Conflict of Interest
Vernhet_coi_disclosure.pdf



Click here to access/download
ICMJE Conflict of Interest
Thibault_coi_disclosure.pdf

